{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T14:13:27Z","timestamp":1782828807691,"version":"3.54.5"},"reference-count":69,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jdiacomp.2024.108780","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:27:42Z","timestamp":1717720062000},"page":"108780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The effect of probiotic consumption on lipid profile, glycemic index, inflammatory markers, and liver function in NAFLD patients: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"38","author":[{"given":"Sadegh","family":"Mozaffari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdeyeh","family":"Aliari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solaleh","family":"Emamgholipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedram Rezaei","family":"Amirkiasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Zare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Katsiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghodratollah","family":"Panahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2024.108780_bb0005","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3390\/metabo13040536","article-title":"Screening for NAFLD\u2014current know- ledge and challenges","volume":"13","author":"Forlano","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0010","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jhep.2023.03.040","article-title":"Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons","volume":"79","author":"Le","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0015","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/1570161115666170621075619","article-title":"Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome?","volume":"16","author":"Katsiki","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0020","doi-asserted-by":"crossref","first-page":"6820","DOI":"10.3748\/wjg.v21.i22.6820","article-title":"Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update","volume":"21","author":"Athyros","year":"2015","journal-title":"World J Gastroenterol: WJG"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0025","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2174\/1570161117666190405164313","article-title":"Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block","volume":"18","author":"Athyros","year":"2020","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0030","first-page":"147","article-title":"From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need","author":"Kokkorakis","year":"2023","journal-title":"Metabolism-Clinical and Experimental"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0035","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.3350\/cmh.2022.0424","article-title":"Non-alcoholic fatty liver disease: definition and subtypes","volume":"29","author":"Han","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0040","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/cld.1170","article-title":"NASH and the gut microbiome: implications for new therapies","volume":"19","author":"Tsay","year":"2022","journal-title":"Clinical Liver Disease"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0045","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.3390\/nu14245261","article-title":"The preva- lence of small intestinal bacterial overgrowth in patients with non-alcoholic liver diseases: NAFLD, NASH, fibrosis, cirrhosis\u2014a systematic review, meta-analysis and meta-regression","volume":"14","author":"Gudan","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0050","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/0898010119879527","article-title":"Dysbiosis of the gut microbiome: a concept analysis","volume":"38","author":"Perez","year":"2020","journal-title":"J Holist Nurs"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0055","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.3748\/wjg.v29.i11.1651","article-title":"Microbiome-liver crosstalk: a multihit therapeutic target for liver disease","volume":"29","author":"Kirundi","year":"2023","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/17474124.2019.1569513","article-title":"Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease","volume":"13","author":"Suk","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0065","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1007\/s00125-023-05966-9","article-title":"The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease","volume":"66","author":"Andreasen","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0070","first-page":"114","article-title":"Making progress towards a better pathophysiological understanding and more promising therapeutic options for treating non-alcoholic steatohepatitis (NASH)\/DASH (dysmetabolism associated steatohepatitis)","author":"Katsiki","year":"2021","journal-title":"Metabolism-Clinical and Experimental"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0075","series-title":"Effects of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors on Non-alcoholic Fatty Liver Disease\/Non-alcoholic Steatohepatitis: Ex Quo et Quo Vadimus?","first-page":"iii","author":"Katsiki","year":"2019"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0080","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/1570161116666171205110801","article-title":"Recent news on statins for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis","volume":"16","author":"Athyros","year":"2018","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.metabol.2017.02.014","article-title":"The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement","volume":"71","author":"Athyros","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0090","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/1570161114999160513150605","article-title":"Resolution of non-alcoholic-steatohepatitis. More than one drug needed?","volume":"14","author":"Athyros V","year":"2016","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0095","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s42000-022-00379-6","article-title":"Semaglutide, cilofexor, and firsocostat for nonalcoholic steatohepatitis: a dance that may need more than one dancer","volume":"21","author":"Polyzos","year":"2022","journal-title":"Hormones"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106679","article-title":"Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): a position paper from the International Lipid Expert Panel (ILEP)","volume":"189","author":"Rizzo","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.artere.2022.07.002","article-title":"Dietary patterns in non-alcoholic fatty liver disease (NAFLD): stay on the straight and narrow path!","volume":"34","author":"Katsiki","year":"2022","journal-title":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis (English Edition)"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0110","first-page":"1090","article-title":"Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial","volume":"15","author":"Aller","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0115","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/1751-2980.12561","article-title":"Treatment efficacy of a probiotic preparation for non-alcoholic steatohepatitis: a pilot trial","volume":"18","author":"Manzhalii","year":"2017","journal-title":"J Dig Dis"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0120","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/apt.12758","article-title":"Randomised clinical trial: the beneficial effects of VSL# 3 in obese children with non-alcoholic steatohepatitis","volume":"39","author":"Alisi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0125","doi-asserted-by":"crossref","first-page":"7386","DOI":"10.3168\/jds.2014-8500","article-title":"Effects of probiotic yogurt consumption on metabolic factors in individuals with nonalcoholic fatty liver disease","volume":"97","author":"Nabavi","year":"2014","journal-title":"J Dairy Sci"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0130","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1665-2681(19)31364-X","article-title":"Treat- ment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study","volume":"12","author":"Wong","year":"2013","journal-title":"Annals Hepatol"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.15403\/jgld.2014.1121.271.kby","article-title":"A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in NAFLD patients: evidence from a randomized clinical trial","volume":"27","author":"Kobyliak","year":"2018","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0140","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/jamainternmed.2018.5403","article-title":"Probiotic safety\u2014no guarantees","volume":"178","author":"Cohen","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0145","doi-asserted-by":"crossref","first-page":"16518","DOI":"10.3748\/wjg.v20.i44.16518","article-title":"Effect of probiotic administration on the intestinal microbiota, current knowledge and potential applications","volume":"20","author":"de LeBlanc","year":"2014","journal-title":"World J Gastroenterol: WJG"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0150","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/nutrit\/nux047","article-title":"Lipid-lowering nutraceuticals in clinical practice: position paper from an international lipid expert panel","volume":"75","author":"Cicero","year":"2017","journal-title":"Nutr Rev"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0155","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/cells12010184","article-title":"Probiotics mechanism of action on immune cells and beneficial effects on human health","volume":"12","author":"Mazziotta","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0160","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/nu12010124","article-title":"Effects of probiotics on metabolic syndrome: a systematic review of randomized clinical trials","volume":"12","author":"Tenorio-Jim\u00e9nez","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2017.06.024","article-title":"Probiotics and gastrointestinal conditions: an overview of evidence from the Cochrane collaboration","volume":"45","author":"Parker","year":"2018","journal-title":"Nutrition"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0170","series-title":"Methods for meta-Analysis in Medical Research","author":"Sutton","year":"2000"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0175","first-page":"343","article-title":"The Cochrane Colla- boration\u2019s tool for assessing risk of bias in randomised trials","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0185","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1111\/1750-3841.15367","article-title":"Effects of probiotic and prebiotic supplemen- tation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: a randomized clinical trial","volume":"85","author":"Behrouz","year":"2020","journal-title":"J Food Sci"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0190","doi-asserted-by":"crossref","first-page":"150","DOI":"10.15171\/mejdd.2017.66","article-title":"Effects of probiotic and prebiotic supplementation on leptin, adiponectin, and glycemic parameters in non-alcoholic fatty liver disease: a randomized clinical trial","volume":"9","author":"Behrouz","year":"2017","journal-title":"Middle East J Dig Dis"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0195","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021464","article-title":"Protective effect of probiotics in patients with non-alcoholic fatty liver disease","volume":"99","author":"Cai","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0200","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/MPG.0000000000001422","article-title":"Effects of probiotics on nonal- coholic fatty liver disease in obese children and adolescents","volume":"64","author":"Famouri","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0205","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/ijo.2015.40","article-title":"Urinary 1H-NMR-based metabolic profiling of children with NAFLD undergoing VSL# 3 treatment","volume":"39","author":"Miccheli","year":"2015","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0210","first-page":"25","article-title":"Effect of probiotic yogurt on enzymes and Ecogenisity of liver in individuals with non alcoholic fatty liver disease: a double-blind randomized controlled clinical trial","volume":"23","author":"Rafraf","year":"2015","journal-title":"J Adv Med Biomed Res"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0215","first-page":"82","article-title":"The effect of gerilact on non-alcoholic fatty liver disease","volume":"27","author":"Sadrkabir","year":"2020","journal-title":"J Kerman Univ Med Sci"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0220","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1080\/07315724.2015.1031355","article-title":"Effects of multi- strain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: a double-blind randomized clinical trial","volume":"35","author":"Sepideh","year":"2016","journal-title":"J Am Coll Nutr"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0225","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/ijo.2017.210","article-title":"Probio- tics administration following sleeve gastrectomy surgery: a randomized double-blind trial","volume":"42","author":"Sherf-Dagan","year":"2018","journal-title":"Int J Obes"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0230","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0235","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.3390\/ijms23063167","article-title":"Usefulness of probiotics in the management of NAFLD: evidence and involved mechanisms of action from preclinical and human models","volume":"23","author":"Arellano-Garc\u00eda","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0240","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.2174\/1389450116666150416120351","article-title":"Targeting the gut microbiota for the treatment of non-alcoholic fatty liver disease","volume":"16","author":"Mouzaki","year":"2015","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0245","first-page":"349","article-title":"Non-alcoholic fatty liver disease","author":"Sattar","year":"2014","journal-title":"Bmj"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0250","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3390\/jcm8040445","article-title":"Utility of ALT concentration in men and women with nonalcoholic fatty liver disease: cohort study","volume":"8","author":"Sung","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0255","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/874768","article-title":"Is there a role for probiotics in liver disease?","volume":"2014","author":"Lo","year":"2014","journal-title":"Scientific World Journal"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0260","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/apt.14327","article-title":"Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey","volume":"46","author":"Wong","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0265","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/dc11-1853","article-title":"Combined influence of insulin resistance, over- weight\/obesity, and fatty liver as risk factors for type 2 diabetes","volume":"35","author":"Sung","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0270","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.3390\/v13071285","article-title":"Findings from studies are congruent with obesity having a viral origin, but what about obesity-related NAFLD?","volume":"13","author":"Tarantino","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0275","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1172\/JCI34275","article-title":"Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice","volume":"118","author":"Postic","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0280","doi-asserted-by":"crossref","DOI":"10.1177\/1756284819878046","article-title":"Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"12","author":"Tang","year":"2019","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0285","article-title":"Efficacy of probiotics on nonalcoholic fatty liver disease: a meta-analysis","volume":"102","author":"Zhou","year":"2023","journal-title":"Medicine"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-42059-3","article-title":"Randomized, double-blind, placebo-controlled study of a multispecies probiotic mixture in nonalcoholic fatty liver disease","volume":"9","author":"Ahn","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0295","doi-asserted-by":"crossref","first-page":"1024678","DOI":"10.3389\/fnut.2022.1024678","article-title":"The effects of supplementation of pro- biotics, prebiotics, or synbiotics on patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"9","author":"Xing","year":"2022","journal-title":"Front Nutr"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0300","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1484598","article-title":"Systematic review with meta-analysis: the effects of probiotics in nonalcoholic fatty liver disease","volume":"2019","author":"Xiao","year":"2019","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0305","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","article-title":"Non-alcoholic fatty liver disease and dyslipidemia: an update","volume":"65","author":"Katsiki","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0310","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-0032-1306423","article-title":"Dyslipidemia in patients with nonalcoholic fatty liver disease","volume":"32","author":"Chatrath","year":"2012","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0315","doi-asserted-by":"crossref","unstructured":"Huang Y, Wang X, Zhang L, Zheng K, Xiong J, Li J, et al. Effect of probiotics therapy on nonalcoholic fatty liver disease. Comput Math Methods Med 2022;2022.","DOI":"10.1155\/2022\/7888076"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0320","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3168\/jds.S0022-0302(04)73164-1","article-title":"Purification and characterization of three different types of bile salt hydrolases from Bifidobacterium strains","volume":"87","author":"Kim","year":"2004","journal-title":"J Dairy Sci"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0325","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/B978-0-12-800100-4.00003-9","article-title":"The role of short-chain fatty acids in health and disease","volume":"121","author":"Tan","year":"2014","journal-title":"Adv Immunol"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0330","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.597648","article-title":"Chronic inflammation in non-alcoholic steatohepatitis: molecular mechanisms and therapeutic strategies","volume":"11","author":"Luci","year":"2020","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0335","doi-asserted-by":"crossref","first-page":"14960","DOI":"10.1080\/21655979.2023.2185941","article-title":"The clinical effect of probiotics on patients with non-alcoholic fatty liver disease: a meta-analysis","volume":"13","author":"Wang","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0340","doi-asserted-by":"crossref","first-page":"1014670","DOI":"10.3389\/fendo.2022.1014670","article-title":"Probiotics for the improvement of metabolic profiles in patients with metabolic-associated fatty liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jdiacomp.2024.108780_bb0345","article-title":"Efficacy of probiotics on nonalcoholic fatty liver disease: a meta-analysis","volume":"102","author":"Zhou","year":"2023","journal-title":"Medicine"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872724001065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872724001065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T05:43:08Z","timestamp":1722058988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872724001065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":69,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1056872724001065"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108780","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of probiotic consumption on lipid profile, glycemic index, inflammatory markers, and liver function in NAFLD patients: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2024.108780","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108780"}}